Identification

Name
Sildenafil
Accession Number
DB00203  (APRD00556)
Type
Small Molecule
Groups
Approved, Investigational
Description

Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5). PDE5 is found in particularly high concentrations in the corpus cavernosum, erectile tissue of the penis. It is also found in the retina and vascular endothelium. Increased cGMP results in vasodilation which facilitates generation and maintenance of an erection. The vasodilatory effects of sildenafil also help reduce symptoms of PAH.

Structure
Thumb
Synonyms
  • 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
External IDs
HIP-0908 / HIP0908
Product Ingredients
IngredientUNIICASInChI Key
Sildenafil CitrateBW9B0ZE037171599-83-0DEIYFTQMQPDXOT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act SildenafilTablet100 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Act SildenafilTablet25 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Act SildenafilTablet50 mgOralActavis Pharma Company2012-11-08Not applicableCanada
Auro-sildenafilTablet25 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-sildenafilTablet50 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-sildenafilTablet100 mgOralAuro Pharma IncNot applicableNot applicableCanada
Dom-sildenafilTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-sildenafilTablet25 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-sildenafilTablet50 mgOralDominion PharmacalNot applicableNot applicableCanada
Gd-sildenafilTablet50 mgOralGenmed A Division Of Pfizer Canada Inc2012-11-272015-08-03Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sildenafilTablet25 mgOralApotex Corporation2012-11-14Not applicableCanada
Apo-sildenafilTablet50 mgOralApotex Corporation2012-11-14Not applicableCanada
Apo-sildenafilTablet100 mgOralApotex Corporation2012-11-09Not applicableCanada
Apo-sildenafil RTablet20 mgOralApotex Corporation2013-12-23Not applicableCanada
SildenafilTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2013-05-31Not applicableUs
SildenafilTablet20 mg/1Oralbryant ranch prepack2012-11-08Not applicableUs
SildenafilTablet, film coated20 mg/1OralLake Erie Medical Dba Quality C2015-11-18Not applicableUs
SildenafilTablet, film coated20 mg/1OralNucare Pharmaceuticals, Inc.2014-01-03Not applicableUs
SildenafilTablet, film coated20 mg/1OralMylan Pharmaceuticals2012-11-09Not applicableUs
SildenafilTablet, film coated20 mg/1OralNorth Star Rx Llc2013-02-262016-10-13Us
Categories
UNII
3M7OB98Y7H
CAS number
139755-83-2
Weight
Average: 474.576
Monoisotopic: 474.204924168
Chemical Formula
C22H30N6O4S
InChI Key
BNRNXUUZRGQAQC-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
IUPAC Name
5-{2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-7-one
SMILES
CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1

Pharmacology

Indication

For the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).

Structured Indications
Pharmacodynamics

Erections are controlled by the parasympathetic nervous system. Upon sexual stimulation, a decrease in vascular resistance is mediated by acetylcholine and nitric oxide resulting in vasodilation. The hemodynamic mechanism of an erection is comprised of five stages. During the latent stage, arterial and carvernous smooth muscle relaxation occurs. Vasodilation results in high levels of blood flow causing the penis to grow to its full size. This stage is called tumescence. During the full-erection stage, blood flow fills penis sinusoids and outflow is restricted. This is followed by the rigid-erection phase during which the cavernous muscles contract causing the penis to become rigid. Little blood flow occurs during this stage. During the final stage, detumescence, the cavernous muscles relax and blood flows out of the penis. Erectile dysfunction may occur when there is insufficient blood supply to the penis or when the penis is unable to prevent outflow of blood from the penis. Sildenafil is a specific inhibitor of PDE5, an enzyme responsible for the breakdown of cGMP to 5’-GMP. Increased levels of cGMP stimulate vasodilation and facilitate the generation and maintenance of erections. These vasodilatory effects also help decrease symptoms of PAH. Sildenfail also exhibits some activity against PDE6 (10 times less potentcy compared to PDE5), a PDE isoform found predmoninantly in the retina. This activity is responsible for the blue tinged vision experienced by users of sildenafil.

Mechanism of action

Sildenafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by sildenafil enhances erectile function by increasing the amount of cGMP.

TargetActionsOrganism
AcGMP-specific 3',5'-cyclic phosphodiesterase
inhibitor
Human
NRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma
inhibitor
Human
NRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma
inhibitor
Human
Absorption

>90% absorbed with ~40% reaching systemic circulation unchanged following first-pass metabolism

Volume of distribution
  • 105 L
Protein binding

96%

Metabolism

Sildenafil appears to be completely metabolized in the liver to 16 metabolites. Its metabolism is mediated mainly by cytochrome P450 microsomal isozymes 3A4 (major route) and 2C9 (minor route). The major circulating metabolite, N-demethylated metabolite, has PDE selectivity similar to the parent drug and ~50% of its in vitro potency. The N-demethylated metabolite is further metabolized to an N-dealkylated N,N-de-ethylated metabolite. Sildenafil also undergoes N-dealkylation followed by N-demethylation of the piperazine ring.

Route of elimination

Sildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).

Half life

4 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Angiotensin-converting enzyme---Not AvailableAlu insertions / Alu insertions  … show all Effect Directly StudiedPatients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunctionDetails
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3---(T;T)T allele, homozygoteEffect Directly StudiedPatients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunctionDetails

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Sildenafil can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Sildenafil can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Sildenafil can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Sildenafil.Approved
AbirateroneThe serum concentration of Sildenafil can be increased when it is combined with Abiraterone.Approved
AcebutololSildenafil may increase the antihypertensive activities of Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Sildenafil.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sildenafil.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sildenafil.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Sildenafil.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Sildenafil.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Sildenafil.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Sildenafil.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Sildenafil.Approved, Illicit
AlfuzosinSildenafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
AliskirenSildenafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Sildenafil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sildenafil.Approved, Investigational
AlogliptinThe serum concentration of Sildenafil can be increased when it is combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Sildenafil.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Sildenafil can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Sildenafil.Approved, Illicit, Investigational
AlprenololSildenafil may increase the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Alprostadil.Approved, Investigational
AmbrisentanSildenafil may increase the antihypertensive activities of Ambrisentan.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Sildenafil.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sildenafil.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Sildenafil.Approved
AmiodaroneThe serum concentration of Sildenafil can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Sildenafil.Approved
AmlodipineSildenafil may increase the antihypertensive activities of Amlodipine.Approved
AmprenavirThe serum concentration of Sildenafil can be increased when it is combined with Amprenavir.Approved
Amyl NitriteSildenafil may increase the vasodilatory activities of Amyl Nitrite.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sildenafil.Approved
Antithrombin III humanThe serum concentration of Sildenafil can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Sildenafil can be increased when it is combined with Apixaban.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Sildenafil.Approved, Investigational
AprepitantThe serum concentration of Sildenafil can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Sildenafil can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Sildenafil.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sildenafil.Approved, Investigational
ArgatrobanThe serum concentration of Sildenafil can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sildenafil.Approved, Investigational
ArmodafinilThe metabolism of Sildenafil can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Sildenafil.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Sildenafil.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Sildenafil.Approved, Withdrawn
AsunaprevirThe serum concentration of Sildenafil can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Sildenafil can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololSildenafil may increase the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Sildenafil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Sildenafil is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Sildenafil.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Sildenafil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Sildenafil.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Sildenafil.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sildenafil.Investigational
BatimastatThe serum concentration of Sildenafil can be increased when it is combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Sildenafil.Approved
BenazeprilThe serum concentration of Sildenafil can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideSildenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved
BenzamidineThe serum concentration of Sildenafil can be increased when it is combined with Benzamidine.Experimental
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sildenafil.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sildenafil.Approved
BepridilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololSildenafil may increase the antihypertensive activities of Betaxolol.Approved
BethanidineSildenafil may increase the antihypertensive activities of Bethanidine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Sildenafil.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Sildenafil.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Sildenafil.Approved
BietaserpineSildenafil may increase the antihypertensive activities of Bietaserpine.Experimental
BimatoprostSildenafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
BisoprololSildenafil may increase the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Sildenafil can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Sildenafil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sildenafil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sildenafil.Approved
BQ-123Sildenafil may increase the antihypertensive activities of BQ-123.Investigational
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Sildenafil.Approved
BretyliumSildenafil may increase the antihypertensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sildenafil.Approved
BrimonidineSildenafil may increase the antihypertensive activities of Brimonidine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Sildenafil.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Sildenafil.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Sildenafil.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Sildenafil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sildenafil.Approved
BucindololSildenafil may increase the hypotensive activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Sildenafil.Approved
BunazosinSildenafil may increase the hypotensive activities of Bunazosin.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Sildenafil.Approved, Investigational
BupranololSildenafil may increase the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sildenafil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Sildenafil can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Sildenafil.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Sildenafil.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Sildenafil.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Sildenafil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Sildenafil.Approved
CadralazineSildenafil may increase the antihypertensive activities of Cadralazine.Experimental
CafedrineSildenafil may increase the antihypertensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Sildenafil.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Sildenafil.Approved, Nutraceutical
CamostatThe serum concentration of Sildenafil can be increased when it is combined with Camostat.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Sildenafil.Approved
CandesartanSildenafil may increase the antihypertensive activities of Candesartan.Experimental
Candesartan cilexetilSildenafil may increase the antihypertensive activities of Candesartan cilexetil.Approved
CandoxatrilThe serum concentration of Sildenafil can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Sildenafil can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Sildenafil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Sildenafil can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Sildenafil can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sildenafil.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Sildenafil.Approved
CarteololSildenafil may increase the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sildenafil.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sildenafil.Approved, Investigational
CeliprololSildenafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Sildenafil.Approved, Vet Approved
CeritinibThe serum concentration of Sildenafil can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Sildenafil.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Sildenafil.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Sildenafil.Approved
ChloramphenicolThe metabolism of Sildenafil can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Sildenafil.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Sildenafil.Approved, Vet Approved
ChlorothiazideSildenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Sildenafil.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Sildenafil.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sildenafil.Approved
ChlorthalidoneSildenafil may increase the antihypertensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Sildenafil.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Sildenafil.Approved, Nutraceutical
CholesterolThe serum concentration of Sildenafil can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Sildenafil can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Sildenafil.Approved, Investigational
CicletanineSildenafil may increase the antihypertensive activities of Cicletanine.Investigational
CilastatinThe serum concentration of Sildenafil can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Sildenafil.Approved
CimetidineThe metabolism of Sildenafil can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Sildenafil can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sildenafil.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Sildenafil.Approved
ClarithromycinThe serum concentration of Sildenafil can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Sildenafil can be decreased when combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Sildenafil.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Sildenafil.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Sildenafil.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Sildenafil.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sildenafil.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Sildenafil.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Sildenafil.Approved, Illicit
ClonidineSildenafil may increase the antihypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Sildenafil.Approved, Nutraceutical
CloranololSildenafil may increase the antihypertensive activities of Cloranolol.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Sildenafil.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sildenafil.Approved, Illicit
ClotrimazoleThe metabolism of Sildenafil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Sildenafil.Approved
CobicistatThe serum concentration of Sildenafil can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sildenafil.Approved
CocaineThe metabolism of Sildenafil can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Sildenafil.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sildenafil.Approved
ConivaptanThe serum concentration of Sildenafil can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Sildenafil.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Sildenafil.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Sildenafil.Approved
CrisaboroleThe metabolism of Sildenafil can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Sildenafil.Approved
CryptenamineSildenafil may increase the antihypertensive activities of Cryptenamine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.Approved
CyclopenthiazideSildenafil may increase the antihypertensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
CyclothiazideSildenafil may increase the antihypertensive activities of Cyclothiazide.Approved
Cyproterone acetateThe serum concentration of Sildenafil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Sildenafil.Approved, Investigational
Dabigatran etexilateThe serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Sildenafil.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Sildenafil.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Sildenafil.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Sildenafil.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Sildenafil.Approved, Investigational
DarexabanThe serum concentration of Sildenafil can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Sildenafil.Approved, Investigational
DarunavirThe serum concentration of Sildenafil can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sildenafil.Approved
DasatinibThe serum concentration of Sildenafil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Sildenafil.Approved
DebrisoquinSildenafil may increase the antihypertensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Sildenafil can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Sildenafil.Approved
DelanzomibThe serum concentration of Sildenafil can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Sildenafil can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Sildenafil can be decreased when combined with Delavirdine.Approved
DeserpidineSildenafil may increase the antihypertensive activities of Deserpidine.Approved
DesipramineThe metabolism of Sildenafil can be decreased when combined with Desipramine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Sildenafil.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Sildenafil.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Sildenafil.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sildenafil.Approved, Investigational
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Sildenafil.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sildenafil.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Sildenafil.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Sildenafil.Approved, Illicit, Vet Approved
DiazoxideSildenafil may increase the antihypertensive activities of Diazoxide.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sildenafil.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sildenafil.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Sildenafil.Approved
diethylnorspermineSildenafil may increase the antihypertensive activities of diethylnorspermine.Investigational
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Sildenafil.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Sildenafil.Approved
DihydralazineSildenafil may increase the antihypertensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Sildenafil.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sildenafil.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Sildenafil.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Sildenafil.Experimental
DihydroergotamineThe metabolism of Sildenafil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemSildenafil may increase the antihypertensive activities of Diltiazem.Approved
DiphenhydramineThe metabolism of Sildenafil can be decreased when combined with Diphenhydramine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Sildenafil.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Sildenafil.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Sildenafil.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Sildenafil.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Sildenafil.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Sildenafil.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sildenafil.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Sildenafil.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Sildenafil.Approved
DorzolamideSildenafil may increase the antihypertensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Sildenafil can be decreased when combined with Dosulepin.Approved
DoxazosinSildenafil may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Sildenafil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sildenafil.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Sildenafil.Approved, Investigational
DoxycyclineThe metabolism of Sildenafil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sildenafil.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Sildenafil.Approved
DuloxetineThe metabolism of Sildenafil can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Sildenafil.Approved, Investigational
EcabetThe serum concentration of Sildenafil can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Sildenafil can be increased when it is combined with Edoxaban.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Sildenafil.Approved, Investigational
EfonidipineSildenafil may increase the antihypertensive activities of Efonidipine.Approved
ElafinThe serum concentration of Sildenafil can be increased when it is combined with Elafin.Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Sildenafil.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sildenafil.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Sildenafil.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Sildenafil.Approved
EnalaprilThe serum concentration of Sildenafil can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Sildenafil can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Sildenafil can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Sildenafil.Approved
EndralazineSildenafil may increase the antihypertensive activities of Endralazine.Experimental
EnzalutamideThe serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide.Approved
EpanololSildenafil may increase the antihypertensive activities of Epanolol.Experimental
Epigallocatechin GallateThe serum concentration of Sildenafil can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Sildenafil.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Sildenafil.Approved
EpoprostenolSildenafil may increase the antihypertensive activities of Epoprostenol.Approved
EprosartanSildenafil may increase the antihypertensive activities of Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Sildenafil.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Sildenafil.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Sildenafil.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Sildenafil.Approved, Investigational
Erythrityl TetranitrateSildenafil may increase the vasodilatory activities of Erythrityl Tetranitrate.Approved, Investigational
ErythromycinThe serum concentration of Sildenafil can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Sildenafil.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Sildenafil can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Sildenafil.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Sildenafil.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Sildenafil.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Sildenafil.Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Sildenafil.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Sildenafil.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Sildenafil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Sildenafil.Approved
EthanolEthanol may increase the hypotensive activities of Sildenafil.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Sildenafil.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Sildenafil.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sildenafil.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Sildenafil.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Sildenafil.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Sildenafil.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sildenafil.Approved, Investigational
EtravirineThe serum concentration of Sildenafil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sildenafil.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Sildenafil.Approved, Investigational
FaldaprevirThe serum concentration of Sildenafil can be increased when it is combined with Faldaprevir.Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Sildenafil.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Sildenafil.Approved
FelodipineSildenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Sildenafil.Approved
FenoldopamSildenafil may increase the antihypertensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Sildenafil.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSildenafil may increase the antihypertensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Sildenafil.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Sildenafil.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Sildenafil.Approved
FloxuridineThe metabolism of Sildenafil can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Sildenafil can be increased when it is combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sildenafil.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Sildenafil.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sildenafil.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Sildenafil.Approved
FluorouracilThe metabolism of Sildenafil can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Sildenafil can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Sildenafil.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Sildenafil.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Sildenafil.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Sildenafil.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Sildenafil.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sildenafil.Approved
FluvoxamineThe metabolism of Sildenafil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Sildenafil.Approved, Investigational
FosamprenavirThe serum concentration of Sildenafil can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sildenafil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Sildenafil can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Sildenafil can be increased when combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Sildenafil.Approved, Investigational
Fusidic AcidThe serum concentration of Sildenafil can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Sildenafil can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Sildenafil.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Sildenafil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Sildenafil.Approved, Investigational
GeldanamycinThe serum concentration of Sildenafil can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Sildenafil can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sildenafil.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Sildenafil.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Sildenafil.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Sildenafil.Approved
GM6001The serum concentration of Sildenafil can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Sildenafil.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Sildenafil.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Sildenafil.Investigational, Withdrawn
GuanabenzSildenafil may increase the antihypertensive activities of Guanabenz.Approved, Investigational
GuanadrelSildenafil may increase the antihypertensive activities of Guanadrel.Approved
GuanazodineSildenafil may increase the antihypertensive activities of Guanazodine.Experimental
GuanethidineSildenafil may increase the antihypertensive activities of Guanethidine.Approved
GuanfacineSildenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
GuanoclorSildenafil may increase the antihypertensive activities of Guanoclor.Experimental
GuanoxabenzSildenafil may increase the antihypertensive activities of Guanoxabenz.Experimental
GuanoxanSildenafil may increase the antihypertensive activities of Guanoxan.Experimental
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Sildenafil.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Sildenafil.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Sildenafil.Approved, Vet Approved
HexamethoniumSildenafil may increase the antihypertensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sildenafil.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Sildenafil.Approved, Investigational
HydralazineSildenafil may increase the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideSildenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Sildenafil.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Sildenafil.Approved, Vet Approved
HydroflumethiazideSildenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sildenafil.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Sildenafil.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Sildenafil.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Sildenafil.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Sildenafil.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sildenafil.Approved
IdelalisibThe serum concentration of Sildenafil can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Sildenafil can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Sildenafil resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Sildenafil.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sildenafil.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Sildenafil.Approved, Investigational
ImidaprilThe serum concentration of Sildenafil can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Sildenafil.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Sildenafil.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Sildenafil.Approved
IndapamideSildenafil may increase the antihypertensive activities of Indapamide.Approved
IndenololSildenafil may increase the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Sildenafil can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Sildenafil.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Sildenafil.Approved, Investigational
IndoraminSildenafil may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.Approved
IrbesartanSildenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Sildenafil.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Sildenafil.Approved, Investigational
IsoflurophateThe serum concentration of Sildenafil can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Sildenafil can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Sildenafil.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Sildenafil.Approved
IsradipineSildenafil may increase the antihypertensive activities of Isradipine.Approved
ItraconazoleThe serum concentration of Sildenafil can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Sildenafil.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Sildenafil.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Sildenafil.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Sildenafil.Approved, Investigational
IxazomibThe serum concentration of Sildenafil can be increased when it is combined with Ixazomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Sildenafil.Approved, Vet Approved
KetanserinSildenafil may increase the antihypertensive activities of Ketanserin.Investigational
KetazolamThe metabolism of Ketazolam can be decreased when combined with Sildenafil.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sildenafil.Approved, Investigational
KetoconazoleThe serum concentration of Sildenafil can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Sildenafil.Approved, Vet Approved
LabetalolSildenafil may increase the hypotensive activities of Labetalol.Approved
LacidipineSildenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Sildenafil.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sildenafil.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Sildenafil.Investigational
LatanoprostSildenafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Sildenafil.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Sildenafil.Approved
LepirudinThe serum concentration of Sildenafil can be increased when it is combined with Lepirudin.Approved
LercanidipineSildenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Sildenafil.Approved
LetaxabanThe serum concentration of Sildenafil can be increased when it is combined with Letaxaban.Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Sildenafil.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Sildenafil.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Sildenafil.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Sildenafil.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Sildenafil.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Sildenafil.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Sildenafil.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Sildenafil.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sildenafil.Approved, Vet Approved
LinagliptinThe serum concentration of Sildenafil can be increased when it is combined with Linagliptin.Approved
LinsidomineSildenafil may increase the antihypertensive activities of Linsidomine.Experimental
LisinoprilThe serum concentration of Sildenafil can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Sildenafil.Approved, Investigational
LobeglitazoneThe metabolism of Sildenafil can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineSildenafil may increase the antihypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Sildenafil.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Sildenafil.Approved
LopinavirThe serum concentration of Sildenafil can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Sildenafil.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sildenafil.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Sildenafil.Approved, Investigational
LosartanSildenafil may increase the antihypertensive activities of Losartan.Approved
LovastatinThe metabolism of Sildenafil can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sildenafil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sildenafil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Sildenafil.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sildenafil.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Sildenafil.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Sildenafil.Illicit, Investigational, Withdrawn
MacitentanSildenafil may increase the antihypertensive activities of Macitentan.Approved
ManidipineSildenafil may increase the antihypertensive activities of Manidipine.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Sildenafil.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Sildenafil.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sildenafil.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Sildenafil.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Sildenafil.Approved
MelagatranThe serum concentration of Sildenafil can be increased when it is combined with Melagatran.Experimental
MelatoninThe metabolism of Melatonin can be decreased when combined with Sildenafil.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sildenafil.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sildenafil.Investigational, Withdrawn
MestranolThe metabolism of Mestranol can be decreased when combined with Sildenafil.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Sildenafil.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Sildenafil.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Sildenafil.Illicit, Withdrawn
MethoserpidineSildenafil may increase the antihypertensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Sildenafil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
MethyldopaSildenafil may increase the antihypertensive activities of Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sildenafil.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Sildenafil.Approved, Vet Approved
Methylpropylpropanediol dinitrateSildenafil may increase the vasodilatory activities of Methylpropylpropanediol dinitrate.Experimental
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sildenafil.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Sildenafil.Approved
MetipranololSildenafil may increase the antihypertensive activities of Metipranolol.Approved
MetolazoneSildenafil may increase the antihypertensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sildenafil.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Sildenafil.Approved
MetyrosineSildenafil may increase the antihypertensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Sildenafil.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sildenafil.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Sildenafil.Approved, Investigational
MibefradilSildenafil may increase the antihypertensive activities of Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Sildenafil.Approved, Illicit
MidostaurinThe metabolism of Sildenafil can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Sildenafil can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilSildenafil may increase the antihypertensive activities of Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Sildenafil.Approved
MirodenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mirodenafil.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sildenafil.Approved
MitotaneThe serum concentration of Sildenafil can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Sildenafil can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Sildenafil.Approved, Investigational
MoexiprilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Sildenafil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Sildenafil.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Sildenafil.Approved, Investigational
MoxonidineSildenafil may increase the antihypertensive activities of Moxonidine.Approved, Investigational
MuzolimineSildenafil may increase the antihypertensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sildenafil.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Sildenafil can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololSildenafil may increase the antihypertensive activities of Nadolol.Approved
NafamostatThe serum concentration of Sildenafil can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilSildenafil may increase the antihypertensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sildenafil.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Sildenafil.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Sildenafil.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sildenafil.Approved, Investigational
NebivololSildenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Sildenafil can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sildenafil can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Sildenafil.Approved, Investigational
NetupitantThe serum concentration of Sildenafil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sildenafil can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Sildenafil can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Sildenafil.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
NicorandilSildenafil may increase the antihypertensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Sildenafil.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Sildenafil.Approved
NiguldipineSildenafil may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Nilotinib can be decreased when combined with Sildenafil.Approved, Investigational
NilvadipineSildenafil may increase the antihypertensive activities of Nilvadipine.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Sildenafil.Approved
NisoldipineSildenafil may increase the antihypertensive activities of Nisoldipine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Sildenafil.Approved
NitrendipineSildenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe serum concentration of Sildenafil can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinSildenafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
NitroprussideSildenafil may increase the antihypertensive activities of Nitroprusside.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Sildenafil.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Sildenafil.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sildenafil.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Sildenafil.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Sildenafil.Approved
OlmesartanSildenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Sildenafil.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Sildenafil.Approved
OmapatrilatThe serum concentration of Sildenafil can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Sildenafil.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Sildenafil.Approved
OsimertinibThe serum concentration of Sildenafil can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sildenafil.Approved
OtamixabanThe serum concentration of Sildenafil can be increased when it is combined with Otamixaban.Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Sildenafil.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Sildenafil.Approved
OxprenololSildenafil may increase the antihypertensive activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Sildenafil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Sildenafil is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Sildenafil.Approved, Vet Approved
PalbociclibThe serum concentration of Sildenafil can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Sildenafil.Approved, Investigational
PanobinostatThe serum concentration of Sildenafil can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Sildenafil.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Sildenafil.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Sildenafil.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Sildenafil.Approved
PargylineSildenafil may increase the antihypertensive activities of Pargyline.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Sildenafil.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Sildenafil.Approved
ParoxetineThe metabolism of Sildenafil can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Sildenafil.Approved
Peginterferon alfa-2bThe serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololSildenafil may increase the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSildenafil may increase the vasodilatory activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Sildenafil.Approved
PentobarbitalThe metabolism of Sildenafil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumSildenafil may increase the antihypertensive activities of Pentolinium.Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Sildenafil.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sildenafil.Approved, Investigational
PerindoprilThe serum concentration of Sildenafil can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Sildenafil.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Sildenafil.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sildenafil.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Sildenafil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sildenafil.Withdrawn
PhenobarbitalThe metabolism of Sildenafil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineSildenafil may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sildenafil.Approved, Investigational
PhentolamineSildenafil may increase the antihypertensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Sildenafil.Approved, Vet Approved
PhenytoinThe metabolism of Sildenafil can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Sildenafil can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Sildenafil.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Sildenafil.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Sildenafil.Approved
PinacidilSildenafil may increase the antihypertensive activities of Pinacidil.Withdrawn
PindololSildenafil may increase the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Sildenafil.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Sildenafil.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sildenafil.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Sildenafil.Approved
Platelet Activating FactorSildenafil may increase the antihypertensive activities of Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Sildenafil.Approved
PolythiazideSildenafil may increase the antihypertensive activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Sildenafil.Approved
PosaconazoleThe serum concentration of Sildenafil can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Sildenafil.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sildenafil.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Sildenafil.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Sildenafil.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Sildenafil.Approved, Vet Approved
PrazosinSildenafil may increase the hypotensive activities of Prazosin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Sildenafil.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Sildenafil.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Sildenafil.Approved
PrimidoneThe metabolism of Sildenafil can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Sildenafil can be increased when it is combined with Prinomastat.Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Sildenafil.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Sildenafil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Sildenafil.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Sildenafil.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Sildenafil.Approved
PropatylnitrateSildenafil may increase the vasodilatory activities of Propatylnitrate.Experimental, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Sildenafil.Approved
PropranololSildenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Sildenafil.Approved
PyrimethamineThe metabolism of Sildenafil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Sildenafil.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Sildenafil.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Sildenafil.Approved, Investigational
QuinaprilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Sildenafil can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Sildenafil.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Sildenafil.Approved, Investigational
RacecadotrilThe serum concentration of Sildenafil can be increased when it is combined with Racecadotril.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Sildenafil.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Sildenafil.Approved, Investigational
RamiprilThe serum concentration of Sildenafil can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sildenafil.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Sildenafil.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Sildenafil.Approved
RemikirenThe serum concentration of Sildenafil can be increased when it is combined with Remikiren.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Sildenafil.Approved, Investigational
RescinnamineSildenafil may increase the antihypertensive activities of Rescinnamine.Approved
ReserpineSildenafil may increase the antihypertensive activities of Reserpine.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Sildenafil.Approved
RibociclibThe serum concentration of Sildenafil can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Sildenafil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sildenafil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sildenafil can be increased when combined with Rifapentine.Approved
RilmenidineSildenafil may increase the antihypertensive activities of Rilmenidine.Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Sildenafil.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Sildenafil.Approved, Investigational
RiociguatSildenafil may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Sildenafil.Approved, Investigational
RitonavirThe serum concentration of Sildenafil can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Sildenafil can be increased when it is combined with Rivaroxaban.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Sildenafil.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Sildenafil.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Sildenafil.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Sildenafil.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sildenafil.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Sildenafil.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sildenafil.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Sildenafil.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Sildenafil.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Sildenafil.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Sildenafil.Approved
S-3304The serum concentration of Sildenafil can be increased when it is combined with S-3304.Investigational
SafinamideThe metabolism of Safinamide can be decreased when combined with Sildenafil.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Sildenafil.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Sildenafil.Approved
SaprisartanSildenafil may increase the antihypertensive activities of Saprisartan.Experimental
SapropterinSapropterin may increase the hypotensive activities of Sildenafil.Approved, Investigational
SaquinavirThe serum concentration of Sildenafil can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Sildenafil can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Sildenafil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Sildenafil.Approved, Investigational, Vet Approved
SelexipagSildenafil may increase the antihypertensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sildenafil.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Sildenafil.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sildenafil.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Sildenafil.Approved, Illicit, Investigational, Withdrawn
SilodosinSildenafil may increase the hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Sildenafil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sildenafil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sildenafil.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SitagliptinThe serum concentration of Sildenafil can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanSildenafil may increase the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Sildenafil can be increased when it is combined with Sivelestat.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Sildenafil.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Sildenafil.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Sildenafil.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Sildenafil.Approved
SpiraprilThe serum concentration of Sildenafil can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Sildenafil can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Sildenafil can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Sildenafil.Approved, Investigational
SulfadiazineThe metabolism of Sildenafil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sildenafil.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Sildenafil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Sildenafil.Approved
SulfisoxazoleThe metabolism of Sildenafil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Sildenafil.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Sildenafil.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Sildenafil.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Sildenafil.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Sildenafil.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Sildenafil.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Sildenafil.Approved, Investigational
TalinololSildenafil may increase the antihypertensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sildenafil.Approved
TamsulosinSildenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sildenafil.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Sildenafil.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Sildenafil.Experimental
TelaprevirThe serum concentration of Sildenafil can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Sildenafil can be increased when it is combined with Telithromycin.Approved
TelmisartanSildenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Sildenafil.Approved
TemocaprilThe serum concentration of Sildenafil can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Sildenafil.Approved
TenitramineSildenafil may increase the vasodilatory activities of Tenitramine.Experimental
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Sildenafil.Approved
TerazosinSildenafil may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Sildenafil can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sildenafil.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Sildenafil.Experimental
TerlipressinSildenafil may increase the antihypertensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Sildenafil.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sildenafil.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Sildenafil.Approved, Vet Approved
TetrahydropalmatineSildenafil may increase the antihypertensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
TheodrenalineSildenafil may increase the antihypertensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sildenafil.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Sildenafil.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sildenafil.Approved, Withdrawn
ThiorphanThe serum concentration of Sildenafil can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Sildenafil.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Sildenafil.Approved
TiboloneSildenafil may increase the antihypertensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Sildenafil.Approved
TiclopidineThe metabolism of Sildenafil can be decreased when combined with Ticlopidine.Approved
TicrynafenSildenafil may increase the antihypertensive activities of Ticrynafen.Withdrawn
TimololSildenafil may increase the antihypertensive activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Sildenafil.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Sildenafil.Approved
TipranavirThe serum concentration of Sildenafil can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Sildenafil.Approved, Investigational
TolazolineSildenafil may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Sildenafil can be decreased when combined with Tolbutamide.Approved
TolonidineSildenafil may increase the antihypertensive activities of Tolonidine.Experimental
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sildenafil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sildenafil.Approved
TopiramateThe metabolism of Sildenafil can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Sildenafil can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideSildenafil may increase the antihypertensive activities of Torasemide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Sildenafil.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Sildenafil.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Sildenafil.Approved, Investigational
TrandolaprilThe serum concentration of Sildenafil can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Sildenafil.Approved
TravoprostSildenafil may increase the antihypertensive activities of Travoprost.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Sildenafil.Approved, Investigational
TreprostinilSildenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sildenafil.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Sildenafil.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Sildenafil.Approved
TrichlormethiazideSildenafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinSildenafil may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sildenafil.Approved
TrimethaphanSildenafil may increase the antihypertensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sildenafil.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sildenafil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sildenafil.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Sildenafil.Approved
TrolnitrateSildenafil may increase the vasodilatory activities of Trolnitrate.Experimental
UbenimexThe serum concentration of Sildenafil can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Sildenafil.Approved, Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Sildenafil.Approved, Investigational
UlinastatinThe serum concentration of Sildenafil can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sildenafil.Approved
UnoprostoneSildenafil may increase the antihypertensive activities of Unoprostone.Approved
UrapidilSildenafil may increase the hypotensive activities of Urapidil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Sildenafil.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Sildenafil.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sildenafil.Approved, Investigational
ValsartanSildenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Sildenafil.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Sildenafil.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Sildenafil.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Sildenafil.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Sildenafil.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Sildenafil.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Sildenafil.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Sildenafil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Sildenafil.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Sildenafil.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Sildenafil.Approved
VildagliptinThe serum concentration of Sildenafil can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Sildenafil.Approved
VincamineSildenafil may increase the antihypertensive activities of Vincamine.Experimental
VincristineThe metabolism of Vincristine can be decreased when combined with Sildenafil.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Sildenafil.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Sildenafil.Approved, Investigational
VinpocetineSildenafil may increase the antihypertensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Sildenafil.Approved
VoriconazoleThe serum concentration of Sildenafil can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sildenafil.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Sildenafil.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Sildenafil.Approved
XimelagatranThe serum concentration of Sildenafil can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideSildenafil may increase the antihypertensive activities of Xipamide.Experimental
XylometazolineSildenafil may increase the antihypertensive activities of Xylometazoline.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Sildenafil.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Sildenafil can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sildenafil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sildenafil.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Sildenafil.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Sildenafil.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Sildenafil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Sildenafil.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Sildenafil can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Sildenafil can be increased when it is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sildenafil.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Sildenafil.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Sildenafil.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Sildenafil.Approved
ZucapsaicinThe metabolism of Sildenafil can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Sildenafil.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Peter James Dunn, Albert Shaw Wood, "Process for preparing sildenafil." U.S. Patent US5955611, issued December, 1994.

US5955611
General References
  1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47-52. [PubMed:8858389]
  2. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999 Jan;33(1):273-82. [PubMed:9935041]
  3. Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5. [PubMed:16275885]
External Links
Human Metabolome Database
HMDB05039
KEGG Drug
D02229
KEGG Compound
C07259
PubChem Compound
5212
PubChem Substance
46508371
ChemSpider
5023
BindingDB
14390
ChEBI
9139
ChEMBL
CHEMBL192
Therapeutic Targets Database
DAP000614
PharmGKB
PA451346
HET
VIA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sildenafil
ATC Codes
G04BE03 — SildenafilG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 24:12.12 — Phosphodiesterase Type 5 Inhibitors
PDB Entries
1tbf / 1udt / 1xos / 2h42 / 3jwq
FDA label
Download (80.5 KB)
MSDS
Download (37.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionImmersion Pulmonary Edema (IPE) / Swimming Induced Pulmonary Edema (SIPE)1
0CompletedTreatmentDermatomyositis / Lupus Erythematosus, Systemic / Raynaud Phenomenon Due to Trauma / Raynaud's Disease / System; Sclerosis / Ultrasound Therapy; Complications1
0RecruitingBasic ScienceMigraine With Aura1
0RecruitingOtherCongenital Heart Disease (CHD) / Liver Cirrhosis1
0RecruitingPreventionHand Foot Skin Reaction1
0TerminatedTreatmentErectile Dysfunction (ED) / Hypogonadism1
1Active Not RecruitingDiagnosticTraumatic Brain Injury (TBI)1
1Active Not RecruitingTreatmentCancer, Breast / Gastrointestinal Cancers / Genitourinary Cancers / Gynecologic Cancers / Sarcomas1
1CompletedNot AvailableErectile Dysfunction (ED)1
1CompletedNot AvailableFemale Sexual Health1
1CompletedNot AvailableNone Volunteer1
1CompletedBasic ScienceErectile Dysfunction (ED)4
1CompletedBasic ScienceErectile Dysfunction (ED) / Prostatic Hyperplasia / Urinary Bladder, Overactive1
1CompletedBasic ScienceGenetic Polymorphic CYP3A5 / Healthy Volunteers / Pharmacokinetics of Three PDE5Is1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic SciencePersistent Pulmonary Hypertension of the Newborn1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionAcute Kidney Injury (AKI)1
1CompletedPreventionHealthy Volunteers1
1CompletedTreatmentChronic Hepatitis C Infection1
1CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
1CompletedTreatmentErectile Dysfunction (ED)2
1CompletedTreatmentHand Foot Syndrome / Palmar Plantar Erythrodysesthesia1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHeart Diseases1
1CompletedTreatmentHypertension, Pulmonary [C08.381.423] / Pulmonary Hypertension (PH)1
1CompletedTreatmentHypertensive1
1CompletedTreatmentPulmonary Arterial Hypertention1
1CompletedTreatmentSickle Cell Disorders1
1RecruitingPreventionLabor Preterm Requiring Hospitalization1
1RecruitingTreatmentCerebral Vasospasm / Subarachnoid Hemorrhage1
1RecruitingTreatmentCombination of Oral Anticoagulation Therapy and Sildenafil / Intermediate-high Risk / Prophylaxis of Pulmonary embolism1
1RecruitingTreatmentNeonatal Encephalopathy1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUrinary Incontinence (UI)1
1TerminatedBasic ScienceCongestive Heart Failure (CHF) / Renal Dysfunction1
1TerminatedTreatmentLiver Cirrhosis1
1TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
1TerminatedTreatmentStroke, Ischemic1
1TerminatedTreatmentStrokes1
1WithdrawnSupportive CareCholangiocarcinomas / Malignant Neoplasm of Pancreas1
1, 2CompletedOtherBMI >30 kg/m2 / Metabolic Syndromes1
1, 2CompletedTreatmentCystic Fibrosis (CF)1
1, 2CompletedTreatmentDysmenorrhea1
1, 2CompletedTreatmentLymphangioma1
1, 2CompletedTreatmentNontuberculous Mycobacterial Infections1
1, 2CompletedTreatmentPulmonary Hypertension (PH)1
1, 2Enrolling by InvitationTreatmentHeart Failure, Unspecified / Renal Dysfunction1
1, 2RecruitingBasic ScienceEndothelial Dysfunction / Insulin Resistance1
1, 2RecruitingTreatmentCystic Fibrosis (CF)1
1, 2RecruitingTreatmentMyelodysplastic Syndromes1
1, 2WithdrawnTreatmentCMRI of Lung Perfusion / Cystic Fibrosis With Mild to Moderate Lung Disease / Lung Perfusion / Lung Vascularization1
2Active Not RecruitingTreatmentCystic Fibrosis (CF)1
2CompletedNot AvailableMild to Moderate Hypertension1
2CompletedBasic ScienceBenign Prostatic Hyperplasia (BPH)1
2CompletedSupportive CareInfertilities1
2CompletedSupportive CareProstate Cancer1
2CompletedTreatmentActive Digital Ulcers1
2CompletedTreatmentAlveolitis, Fibrosing / Pulmonary Fibrosis / Pulmonary Hypertension (PH)1
2CompletedTreatmentBecker's Muscular Dystrophy (BMD)1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentEmphysema / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentErectile Dysfunction (ED)4
2CompletedTreatmentFemale Sexual Arousal Disorder1
2CompletedTreatmentHeart Failure, Unspecified1
2CompletedTreatmentHypertensive1
2CompletedTreatmentHypoactive Sexual Desire Disorder (HSDD)1
2CompletedTreatmentHypoplastic Left Heart Syndrome (HLHS) / Tricuspid Atresia1
2CompletedTreatmentMenière's Disease1
2CompletedTreatmentNAFLD1
2CompletedTreatmentNeonates and Preterm Infants1
2CompletedTreatmentPost-Concussive Syndrome / Traumatic Brain Injury (TBI)1
2CompletedTreatmentPulmonary Fibrosis / Pulmonary Hypertension (PH)1
2CompletedTreatmentPulmonary Hypertension (PH)3
2CompletedTreatmentSexual arousal disorders / Sexual Dysfunctions, Psychological1
2CompletedTreatmentSexual arousal disorders1
2CompletedTreatmentWaldenstrom's Macroglobulinemia (WM)1
2Enrolling by InvitationTreatmentPortopulmonary Hypertension1
2Not Yet RecruitingPreventionAtherosclerosis / Rheumatoid Arthritis1
2Not Yet RecruitingTreatmentChronic Lung Disease of Prematurity1
2Not Yet RecruitingTreatmentIntrauterine Growth Restriction1
2RecruitingSupportive CareLymphatic Diseases / Lymphatic Malformations1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBrain and Nervous System / Glioblastomas / Gliomas / Malignant Gliomas / Recurrent Adult Brain Neoplasm / WHO Grade III Glioma1
2RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2SuspendedTreatmentBecker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD)1
2TerminatedHealth Services ResearchAge-Related Macular Degeneration (ARMD)1
2TerminatedTreatmentParkinson's Disease (PD)1
2TerminatedTreatmentPersistent Pulmonary Hypertension / Respiratory Failure1
2TerminatedTreatmentPriapism / Sickle Cell Disorders1
2TerminatedTreatmentPulmonary Hypertension (PH)2
2TerminatedTreatmentPulmonary Hypertension (PH) / Sickle Cell Disorders1
2TerminatedTreatmentProphylaxis of preeclampsia1
2WithdrawnPreventionCerebral Vasospasm / Rupture of Intracranial Aneurysm / Subarachnoid Hemorrhage1
2WithdrawnPreventionCerebral Vasospasm / Subarachnoid Hemorrhage1
2WithdrawnTreatmentPersistent Pulmonary Hypertension of the Newborn1
2, 3Active Not RecruitingTreatmentDiseases of Mitral Valve / Pulmonary Hypertension (PH)1
2, 3CompletedTreatmentDiastolic Heart Failure / Pulmonary Hypertension (PH)1
2, 3CompletedTreatmentHeart Failure, Unspecified1
2, 3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3CompletedTreatmentPulmonary Hypertension (PH) / Thalassaemic disorders1
2, 3CompletedTreatmentRaynaud's Phenomenon1
2, 3Not Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2, 3Not Yet RecruitingTreatmentPreterm Preeclampsia1
2, 3RecruitingTreatmentErectile Dysfunction (ED)1
2, 3RecruitingTreatmentIntrauterine Growth Restriction (IUGR) / Intrauterine Growth Retardation1
2, 3RecruitingTreatmentIntrauterine Growth Retardation1
2, 3Unknown StatusTreatmentCardiovascular Disease (CVD) / Chronic Lung Diseases / Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH) / Tanshinone IIA Sulfonate1
2, 3Unknown StatusTreatmentIntrauterine Growth Retardation1
3CompletedPreventionErectile Dysfunction (ED) / Prostate Cancer1
3CompletedTreatmentChronic Lung Diseases1
3CompletedTreatmentCongestive Heart Failure (CHF)2
3CompletedTreatmentDiabetes1
3CompletedTreatmentDiffuse Systemic Sclerosis / Raynaud's Phenomenon / Scleroderma, Limited / Scleroderma, Systemic1
3CompletedTreatmentEisenmenger's Syndrome1
3CompletedTreatmentEndothelial Dysfunction / Type 2 Diabetes Mellitus1
3CompletedTreatmentErectile Dysfunction (ED)2
3CompletedTreatmentHeart Failure, Diastolic / Pulmonary Hypertension (PH)1
3CompletedTreatmentHeart Failure, Unspecified3
3CompletedTreatmentIntrauterine Growth Retardation1
3CompletedTreatmentPeripheral Obliterative Arteriopathy1
3CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
3CompletedTreatmentPulmonary Arterial Hypertension, Children1
3CompletedTreatmentPulmonary Fibrosis / Pulmonary Hypertension (PH)1
3CompletedTreatmentPulmonary Hypertension (PH)4
3CompletedTreatmentScleroderma, Systemic1
3Not Yet RecruitingTreatmentPeripheral Obliterative Arteriopathy1
3RecruitingTreatmentHeart Failure, Unspecified / Pulmonary Hypertension (PH)1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentPulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
3RecruitingTreatmentPulmonary Hypertension (PH) / Systolic Dysfunction1
3RecruitingTreatmentPulmonary Hypertension, Familial Persistent, of the Newborn1
3SuspendedTreatmentHypertensive1
3TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
3TerminatedTreatmentPulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)2
3TerminatedTreatmentPulmonary Hypertension (PH)1
3Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
3Unknown StatusTreatmentErectile Dysfunction (ED)1
3Unknown StatusTreatmentPersistent Fetal Circulation Syndrome1
3WithdrawnNot AvailablePulmonary Hypertension (PH)1
3WithdrawnTreatmentArteriospasm coronary1
4Active Not RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
4Active Not RecruitingTreatmentUreteral Stones / Urolithiasis1
4CompletedNot AvailableErectile Dysfunction (ED)3
4CompletedDiagnosticPulmonary Arterial Hypertension (PAH) / Ventricular Dysfunction, Left1
4CompletedEducational/Counseling/TrainingBlindness1
4CompletedPreventionHigh Altitude Pulmonary Edema / Other and unspecified effects of high altitude1
4CompletedTreatmentAngina Pectoris1
4CompletedTreatmentAortic Valve Stenosis1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)2
4CompletedTreatmentDepression / Erectile Dysfunction (ED)1
4CompletedTreatmentDepression / Sexual Dysfunctions1
4CompletedTreatmentDiabetes / Erectile Dysfunction (ED) / Testosterone Deficiency1
4CompletedTreatmentDiabetic Neuropathies1
4CompletedTreatmentEndometrial Preparation / Frozen Embryo Transfer1
4CompletedTreatmentEndothelial Dysfunction / Type 2 Diabetes Mellitus1
4CompletedTreatmentErectile Disfunction / Hemodialysis-dependent patients1
4CompletedTreatmentErectile Dysfunction (ED)20
4CompletedTreatmentErectile Dysfunction (ED) / Hypertensive1
4CompletedTreatmentErectile Dysfunction (ED) / Parkinsons's Disease1
4CompletedTreatmentErectile Dysfunction (ED) / Spinal Cord Injuries (SCI) / Spinal Cord Trauma1
4CompletedTreatmentErectile Dysfunction (ED) / Type 2 Diabetes Mellitus1
4CompletedTreatmentHeart Failure, Diastolic1
4CompletedTreatmentHeart Failure, Unspecified / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
4CompletedTreatmentMeconium Aspiration Syndrome / Persistent Pulmonary Hypertension of Newborn (PPHN)1
4CompletedTreatmentPulmonary Arterial Hypertension (PAH)3
4CompletedTreatmentPulmonary Hypertension (PH) / Valvular Heart Disease1
4CompletedTreatmentPulmonary Hypertension Associated With Connective Tissue Disease1
4CompletedTreatmentQuality of Life1
4CompletedTreatmentSafety1
4CompletedTreatmentSchizophrenic Disorders1
4No Longer AvailableNot AvailablePulmonary Arterial Hypertension (PAH)1
4Not Yet RecruitingBasic ScienceHealthy Volunteers1
4Not Yet RecruitingTreatmentInfertilities1
4Not Yet RecruitingTreatmentLife Change Events / Pulmonary Arterial Hypertension (PAH)1
4RecruitingBasic ScienceEmphysema1
4RecruitingTreatmentArterial Hypertension / Erectile Dysfunction (ED)1
4RecruitingTreatmentAssociated Pulmonary Arterial Hypertension1
4RecruitingTreatmentBMI >30 kg/m21
4RecruitingTreatmentIVF Failure1
4RecruitingTreatmentMitral Valve Surgery / Pulmonary Hypertension (PH)1
4RecruitingTreatmentPulmonary Arterial Hypertension (PAH)2
4Temporarily Not AvailableNot AvailablePulmonary Arterial Hypertension (PAH)1
4TerminatedTreatmentHeart Failure With Reactive Pulmonary Hypertension1
4TerminatedTreatmentHernia, Diaphragmatic / Hypoplasia, Pulmonary / Pulmonary Hypertension (PH)1
4TerminatedTreatmentProstatitis1
4TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
4Unknown StatusTreatmentCardiopulmonary Bypass1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Idiopathic Pulmonary Fibrosis (IPF)1
4Unknown StatusTreatmentErectile Dysfunction (ED)3
4Unknown StatusTreatmentErectile Dysfunction (ED) / Prostatic Neoplasms1
4Unknown StatusTreatmentFontan Circulation1
4Unknown StatusTreatmentHeart Failure, Unspecified1
4Unknown StatusTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD) / Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
4Unknown StatusTreatmentMyalgic Encephalomyelitis (ME)1
4Unknown StatusTreatmentPulmonary Arterial Hypertension (PAH)1
4Unknown StatusTreatmentPulmonary Hypertension Secondary to Lung Disease and/or Hypoxia1
4Unknown StatusTreatmentRecurrent Miscarriages1
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
4WithdrawnTreatmentSickle Cell Disorders1
Not AvailableActive Not RecruitingTreatmentErectile Dysfunction (ED) / Penile Cancer / Radical Prostatectomy1
Not AvailableAvailableNot AvailablePulmonary Arterial Hypertension (PAH)1
Not AvailableCompletedNot AvailableAcute iron intoxication / Beta-Thalassemia / Bone destruction / Hematologic Diseases / Pulmonary Hypertension (PH) / Thalassaemic disorders / Thalassemia Major (TM)1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedNot AvailableHypertensive / Multiple System Atrophy (MSA) / Progressive autonomic failure1
Not AvailableCompletedNot AvailableProstate Cancer1
Not AvailableCompletedNot AvailablePulmonary Arterial Hypertension (PAH)2
Not AvailableCompletedNot AvailablePulmonary Hypertension (PH)2
Not AvailableCompletedBasic ScienceAir Pollution / Exercise Performance / Pulmonary Artery Pressure / Pulmonary Hypertension (PH)1
Not AvailableCompletedDiagnosticCongenital Heart Disease (CHD)1
Not AvailableCompletedDiagnosticDiffuse Parenchymal Lung Diseases / Pulmonary Hypertension (PH)1
Not AvailableCompletedHealth Services ResearchBMI >30 kg/m21
Not AvailableCompletedSupportive CareErectile Dysfunction (ED) / Prostate Cancer / Stage I Prostate Cancer / Stage II Prostate Cancer1
Not AvailableCompletedSupportive CareKidney Tumors1
Not AvailableCompletedSupportive CareProstate Cancer / Psychosocial Effects of Cancer and Its Treatment / Radiation Toxicity / Sexual Dysfunctions / Sexuality and Reproductive Issues1
Not AvailableCompletedTreatmentAging / Tiredness1
Not AvailableCompletedTreatmentComplications, Pregnancy1
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableCompletedTreatmentNephrogenic Diabetes Insipidus1
Not AvailableCompletedTreatmentPulmonary Arterial Hypertension (PAH)1
Not AvailableCompletedTreatmentTiredness1
Not AvailableRecruitingNot AvailableTbi1
Not AvailableRecruitingDiagnosticEndometrial Thickness1
Not AvailableRecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
Not AvailableRecruitingTreatmentComplications, Pregnancy1
Not AvailableRecruitingTreatmentImprove Endothelial Function and Decrease Vascular Stenosis1
Not AvailableTerminatedNot AvailableCardiac Allograft Vasculopathy1
Not AvailableTerminatedSupportive CareErectile Dysfunction (ED) / Erectile Dysfunction Following Radical Prostatectomy / Erectile Dysfunction Following Simple Prostatectomy / Prostate Cancer1
Not AvailableUnknown StatusBasic ScienceCongenital Heart Disease (CHD)1
Not AvailableUnknown StatusDiagnosticErectile Dysfunction (ED)1
Not AvailableUnknown StatusEducational/Counseling/TrainingErectile Dysfunction (ED)1
Not AvailableUnknown StatusTreatmentProstate Cancer1
Not AvailableWithdrawnTreatmentPrimary and Secondary Pulmonary Hypertension1

Pharmacoeconomics

Manufacturers
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral25 mg
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
Injection, solutionIntravenous.8 mg/mL
Injection, solutionIntravenous0.8 mg/ml
Powder, for suspensionOral10 mg/ml
SolutionIntravenous0.8 mg
TabletOral20 mg
Tablet, film coatedOral20 mg
Injection, solutionIntravenous10 mg/12.5mL
TabletOral20 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral25 mg
Tablet, film coatedOral50 mg
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, orally disintegratingOral50 mg
Tablet, orally disintegratingOral100 mg
Tablet, orally disintegratingOral25 mg
Prices
Unit descriptionCostUnit
Sildenafil citrate powder24.38USD g
Viagra 50 mg tablet19.45USD tablet
Viagra 100 mg tablet19.45USD tablet
Viagra 25 mg tablet19.45USD tablet
Revatio 20 mg tablet17.5USD tablet
Revatio 10 mg/12.5 ml vial9.33USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5250534No1995-03-272012-03-27Us
CA2324324No2005-12-202020-10-26Canada
CA2044748No1998-02-032011-06-17Canada
US6469012Yes2000-04-222020-04-22Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)189-190 °CNot Available
water solubility3.5 mg/mLNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.433 mg/mLALOGPS
logP2.35ALOGPS
logP1.65ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)7.27ChemAxon
pKa (Strongest Basic)5.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area109.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.44 m3·mol-1ChemAxon
Polarizability51.18 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6461
Caco-2 permeable+0.7078
P-glycoprotein substrateSubstrate0.7753
P-glycoprotein inhibitor IInhibitor0.672
P-glycoprotein inhibitor IIInhibitor0.8877
Renal organic cation transporterNon-inhibitor0.648
CYP450 2C9 substrateNon-substrate0.6553
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7254
CYP450 1A2 substrateNon-inhibitor0.823
CYP450 2C9 inhibitorInhibitor0.6864
CYP450 2D6 inhibitorNon-inhibitor0.8394
CYP450 2C19 inhibitorNon-inhibitor0.8222
CYP450 3A4 inhibitorInhibitor0.849
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5839
Ames testNon AMES toxic0.5683
CarcinogenicityNon-carcinogens0.6658
BiodegradationNot ready biodegradable0.7641
Rat acute toxicity2.6730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8664
hERG inhibition (predictor II)Inhibitor0.7602
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0002900000-b281f59f40caaba85ac9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-4436900000-0c5804e76b9d495c76d6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0459-6292000000-5a32bfcdda2067978be9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0001900000-51b4957d0b3d25c41773
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01vk-0302900000-86c63c2fd17f7c5b7d6f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03dj-8916100000-e941afc576d544ed32a7
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0059-2494500000-e3f8387aee5a0463363c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05s0-3892000000-aa19715309275e16a6c0

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Pyrazolopyrimidines / Benzenesulfonyl compounds / Phenoxy compounds / Phenol ethers / Pyrimidones / Alkyl aryl ethers / N-methylpiperazines / Organosulfonamides / Sulfonyls / Pyrazoles
show 7 more
Substituents
Benzenesulfonamide / Pyrazolopyrimidine / Benzenesulfonyl group / Phenoxy compound / Phenol ether / Alkyl aryl ether / Pyrimidone / N-methylpiperazine / N-alkylpiperazine / Piperazine
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, piperazines, pyrazolopyrimidine (CHEBI:9139)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, ...
Gene Name
PDE5A
Uniprot ID
O76074
Uniprot Name
cGMP-specific 3',5'-cyclic phosphodiesterase
Molecular Weight
99984.14 Da
References
  1. Carson CC: Long-term use of sildenafil. Expert Opin Pharmacother. 2003 Mar;4(3):397-405. [PubMed:12614192]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Corbin JD, Francis SH, Webb DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002 Sep;60(2 Suppl 2):4-11. [PubMed:12414329]
  4. Kruuse C, Thomsen LL, Birk S, Olesen J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 Jan;126(Pt 1):241-7. [PubMed:12477710]
  5. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA: PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 2003 Feb 3;22(3):469-78. [PubMed:12554648]
  6. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H: Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem. 2006 Jul 28;281(30):21469-79. Epub 2006 May 30. [PubMed:16735511]
  7. Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24. [PubMed:17959709]
  8. Wang J, Re J, Wang Z: [Mode of action of sildenafil]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999 Dec;21(6):493-6. [PubMed:12567500]
  9. Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3. [PubMed:17979301]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Enzyme inhibitor activity
Specific Function
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name
PDE6G
Uniprot ID
P18545
Uniprot Name
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma
Molecular Weight
9643.09 Da
References
  1. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. Epub 2006 Jun 6. [PubMed:16815627]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Enzyme inhibitor activity
Specific Function
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name
PDE6H
Uniprot ID
Q13956
Uniprot Name
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma
Molecular Weight
9074.36 Da
References
  1. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. Epub 2006 Jun 6. [PubMed:16815627]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48. [PubMed:11298070]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. doi: 10.1124/dmd.107.020099. Epub 2008 Feb 28. [PubMed:18308836]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Hyland R, Roe EG, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48. [PubMed:11298070]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Jedlitschky G, Burchell B, Keppler D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74. [PubMed:10893247]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34